Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Leerink Partners

Tracked across 26 events · 853 articles · First seen May 16, 2025 · Last active Sep 22, 2026

Sentiment
12
Attention
9
Events
26
Relationships
14
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 60
Business
Impact: Leerink Partners served as joint book-running manager, benefiting from underwriting fees and strengthening its healthcare franchise.
Aug 05, 2026 · 15 articles
4 60
Business
Impact: Leerink Partners served as a lead book-running manager, generating underwriting revenue and reinforcing its expertise in healthcare IPOs. The deal enhances its reputation in the sector.
Aug 07, 2026 · 8 articles
2 10
Business
Impact: Leerink Partners is acting as the sole bookrunning manager for Amanat Acquisition Corporation's IPO, responsible for managing the offering.
May 19, 2026 · 6 articles
4 10
Business
Impact: Leerink Partners is acting as a joint bookrunning manager for the public offering by Tango Therapeutics, assisting in the sale of securities.
Jun 08, 2026 · 8 articles
4 20
Business
Impact: Leerink Partners acted as a joint book-running manager for Kailera Therapeutics's IPO, facilitating the offering and earning underwriting fees.
Apr 16, 2026 · 8 articles
4 10
Business
Impact: Leerink Partners is acting as a joint book-running manager for Trevi Therapeutics' public offering.
Apr 16, 2026 · 7 articles
2 20
Business
Impact: Leerink Partners acted as joint bookrunning manager, earning underwriting fees and strengthening its relationship with Kazia. The successful offering enhances its reputation in biotech capital markets.
Jul 20, 2026 · 22 articles
2 5
Business
Impact: Leerink Partners is a joint book-running manager, participating in the offering and earning fees.
Aug 04, 2026 · 6 articles
4 10
Business
Impact: Leerink Partners is acting as an active book-running manager for the initial public offering of Parabilis Medicines.
Jun 10, 2026 · 7 articles
4 0
Business
Impact: Leerink Partners is acting as a joint bookrunning manager for Neurogene's public offering.
Jun 30, 2026 · 6 articles
4 60
Business
Impact: Leerink Partners acted as a joint book-running manager for the IPO, earning fees and enhancing its reputation in biotech capital markets.
Jul 06, 2026 · 25 articles
2 10
Business
Impact: Leerink Partners acted as lead placement agent for the private placement, facilitating the transaction and earning fees.
Aug 28, 2026 · 6 articles
2 5
Business
Beta Bionics, Inc. (Nasdaq: BBNX), a commercial-stage medical device company focused on insulin delivery solutions for people with diabetes, completed an underwritten public offering of common stock. On September 15, 2026, Beta Bionics announced its…
Impact: Leerink Partners served as a joint book-running manager for the offering, adding to its healthcare-focused investment banking deal flow.
Sep 15, 2026 · 7 articles
0 0
Business
Impact: Leerink Partners is hosting the Therapeutics Forum where Immunic will have one-on-one meetings.
Jul 09, 2026 · 8 articles
3 0
Business
Impact: Served as lead financial advisor to XOMA Royalty.
Jul 14, 2026 · 6 articles
4 30
Business
Impact: Leerink Partners acted as financial advisor to Fulcrum Therapeutics in the merger.
Aug 17, 2026 · 6 articles
4 0
Regulatory
Impact: Leerink Partners modeled $2 billion sales by 2035, translating to $470 million in royalties for Protagonist, providing a benchmark for valuation.
Aug 28, 2026 · 6 articles
2 5
Business
Lisata Therapeutics acquired Marea Therapeutics, a clinical-stage biotechnology company developing next-generation medicines for cardioendocrine diseases, in a stock-for-stock transaction. All of Marea's outstanding equity interests were exchanged for 1,793,129 shares of Lisata common stock and…
Impact: Served as financial advisor to Marea on the acquisition.
Sep 17, 2026 · 6 articles
7 -10
Business
Impact: Leerink Partners has a neutral rating and a $131 price target, citing regulatory and technology uncertainties.
Jun 18, 2026 · 319 articles
4 0
Business
Impact: Leerink Partners served as exclusive financial advisor to Obsidian Therapeutics, Inc. and acted as a placement agent for the private placement financing.
Apr 14, 2026 · 7 articles
6 0
Business
Impact: Leerink Partners>>> served as an advisor to GSK plc>>> in the acquisition.
Jun 09, 2026 · 56 articles
9 0
Business
Impact: Leerink Partners is a research firm whose analyst, Craig Moffett, offered a measured reception to the Siri AI updates.
May 19, 2026 · 254 articles
6 5
Business
Impact: Investment bank; previously commented on Palsonify's approval.
Jul 06, 2026 · 34 articles
2 0
Regulatory
Impact: Leerink analyst Andrew Berens commented that the launch delay was not anticipated.
Jul 17, 2026 · 7 articles
2 0
Business
Impact: Leerink Partners provided analyst commentary on the acquisitions.
Jul 20, 2026 · 7 articles
4 0
Business
Apr 01, 2026 · 6 articles
Stifel ↔ Leerink Partners
Stifel ↔ Leerink Partners
Guggenheim Partners ↔ Leerink Partners
Guggenheim Partners ↔ Leerink Partners
Morgan Stanley ↔ Leerink Partners
Morgan Stanley ↔ Leerink Partners
Goldman Sachs ↔ Leerink Partners
Goldman Sachs ↔ Leerink Partners
Nasdaq ↔ Leerink Partners
Nasdaq ↔ Leerink Partners
ERGEN INTELLIGENCE
Track Leerink Partners live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.